BT-RADS在治疗后原发性脑肿瘤随访MRI评估中的评分者间一致性
本回顾性研究纳入98例治疗后的原发性脑肿瘤患者共103次MRI,由4名神经放射科医师和2名住院医师独立盲法评分BT-RADS,全体评分者Gwet AC2为0.83(95%CI:0.78-0.87),神经放射科医师组与住院医师组间无统计学差异(P=.36),结论认为评分者间一致性很好,但需进一步研究其能否转化为临床诊疗的一致性提升。
要点
- BT-RADS评分在6名不同经验评分者间Gwet AC2为0.83(95%CI:0.78-0.87),一致性很好。
- 神经放射科医师组Gwet AC2为0.84、住院医师组为0.79,两组间无统计学差异(P=.36)。
- 神经放射科医师盲法评分与事后参考评分的符合率范围为41%-52%。
核心结论
- 独立盲法评分者按BT-RADS标准解读肿瘤报告时评分者间一致性很好,但需进一步研究以确定这种高总体一致性是否能转化为临床诊疗中更大的一致性。
研究设计与样本
- 回顾性研究,纳入2019年1月至2019年2月间98例既往诊断为原发性脑肿瘤并接受治疗成人患者的103次连续MRI检查,6名评分者(4名神经放射科医师和2名放射科住院医师)独立盲法评分,参考标准为至少1名神经放射科医师评分不同时进行共识评分以及利用后续影像和临床信息由2名评分者事后制定的参考评分。
诊断标准与关键数值
- 全体6名评分者间Gwet AC2为0.83(95%CI:0.78-0.87);神经放射科医师组Gwet AC2为0.84(95%CI:0.79-0.89),住院医师组为0.79(95%CI:0.72-0.86),两组比较χ2=0.85、P=.36;103次检查中4名神经放射科医师评分完全一致57次、3名一致21次、2名一致21次;神经放射科医师盲法评分与事后参考评分符合率范围为41%-52%。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 需进一步研究以确定这种高总体一致性是否能转化为临床诊疗中更大的一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The Brain Tumor Reporting and Data System (BT-RADS) is a structured radiology reporting algorithm that was introduced to provide uniformity in posttreatment primary brain tumor follow-up and reporting, but its interrater reliability (IRR) assessment has not been widely studied. Our goal is to evaluate the IRR among neuroradiologists and radiology residents in the use of BT-RADS.
MATERIALS AND METHODS: This retrospective study reviewed 103 consecutive MR studies in 98 adult patients previously diagnosed with and treated for primary brain tumor (January 2019 to February 2019). Six readers with varied experience (4 neuroradiologists and 2 radiology residents) independently evaluated each case and assigned a BT-RADS score. Readers were blinded to the original score reports and the reports from other readers. Cases in which at least 1 neuroradiologist scored differently were subjected to consensus scoring. After the study, a post hoc reference score was also assigned by 2 readers by using future imaging and clinical information previously unavailable to readers. The interrater reliabilities were assessed by using the Gwet AC2 index with ordinal weights and percent agreement.
RESULTS: Of the 98 patients evaluated (median age, 53 years; interquartile range, 41-66 years), 53% were men. The most common tumor type was astrocytoma (77%) of which 56% were grade 4 glioblastoma. Gwet index for interrater reliability among all 6 readers was 0.83 (95% CI: 0.78-0.87). The Gwet index for the neuroradiologists' group (0.84 [95% CI: 0.79-0.89]) was not statistically different from that for the residents' group (0.79 [95% CI: 0.72-0.86]) (χ2 = 0.85; P = .36). All 4 neuroradiologists agreed on the same BT-RADS score in 57 of the 103 studies, 3 neuroradiologists agreed in 21 of the 103 studies, and 2 neuroradiologists agreed in 21 of the 103 studies. Percent agreement between neuroradiologist blinded scores and post hoc reference scores ranged from 41%-52%.
CONCLUSIONS: A very good interrater agreement was found when tumor reports were interpreted by independent blinded readers by using BT-RADS criteria. Further study is needed to determine if this high overall agreement can translate into greater consistency in clinical care.
引用
- Essien M, Cooper ME, Gore A, et al. Interrater Agreement of BT-RADS for Evaluation of Follow-up MRI in Patients with Treated Primary Brain Tumor. AJNR Am J Neuroradiol. 2024. PMID: 38684320. doi:10.3174/ajnr.A8322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。